Sangamo BioSciences Announces Presentation At Regen Med Investor Day

     Sangamo BioSciences Announces Presentation At Regen Med Investor Day

PR Newswire

RICHMOND, Calif., April 10, 2013

RICHMOND, Calif., April 10, 2013 /PRNewswire/ --Sangamo BioSciences, Inc.
(NASDAQ: SGMO) announced today thatEdward Lanphier, Sangamo's president and
CEO, will present at the 2013 Regen Med Investor Day to be held Wednesday,
April 17, 2013 in New York City.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with
leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this
flagship event features 16 of the regenerative medicine field's leading small-
and mid-cap companies.

The following are specific details regarding Sangamo BioSciences' presentation
at the conference:

Event:    ARM's Regen Med Investor Day
Date:     April 17, 2013
Time:     2:45pm EST
Location: Harmonie Club, 4 East 60th Street, New York, NY 10022

The presentation will be webcast live and may be accessed via a link on the
Sangamo BioSciences website in the Investor Relations section under Events and
Presentations. The presentation will be archived on both the Sangamo and ARM
websites after the event.

The event also includes disease indication-focused discussions between key
opinion leaders, top analysts and senior executives from the sector and
keynote-style talks by Jeff Jonas, President of Shire Regenerative Medicine
and Kieran Murphy, President and CEO, GE Healthcare Life Sciences.

Attendance at this event is for credentialed investors and members of the
media only. If you are interested in attending, please contact Laura Parsons
at lparsons@alliancerm.org. Please visit
http://alliancerm.org/event/regen-med-investor-day for more information.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel
DNA-binding proteins for therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS. Sangamo's
other therapeutic programs are focused on monogenic diseases, including
hemophilia, Huntington's disease andhemoglobinopathies such as
beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable
the engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs)
for gene modification and ZFP transcription factors (ZFP TFs) that can control
gene expression and, consequently, cell function. Sangamo has entered into a
strategic collaboration with Shire AG to develop therapeutics for hemophilia,
Huntington's disease and other monogenic diseases and has established
strategic partnerships with companies in non-therapeutic applications of its
technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more
information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Website: http://www.sangamo.com
Contact: Elizabeth Wolffe, Ph.D, +1-510-970-6000, x271, ewolffe@sangamo.com
 
Press spacebar to pause and continue. Press esc to stop.